Brad Hively
Director at Oncology Institute, Inc. (STLN); Director at Starling Oncology, Inc. (STLN)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $2.0M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 24SEC | STLNStarling Oncology, Inc. | Sell Plan | 298,853411,976 held (−42%) | $6.51 | $1.9M | -1.2% |
| Dec 16SEC | STLNOncology Institute, Inc. | Sell | 13,333683,721 held (−2%) | $3.77 | $50K | +70.6% |
- Sell
Director Brad Hively sold $1.9M of STLN at $6.51 — cuts the stake by 42%; pre-scheduled 10b5-1 plan sale.